Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (NASDAQ:IBRX) is among the 12 Best Performing Stocks in February.
On March 4, 2026, Piper Sandler analyst Patrick Soon-Shiong increased ImmunityBio, Inc. (NASDAQ:IBRX)'s price objective to $12 from $7, maintaining an Overweight rating. The firm pointed out ANKTIVA's strong commercial momentum, reporting U.S. net revenues of approximately $113 million in 2025, noting a roughly 700% increase. Piper Sandler now forecasts ANKTIVA revenue of $195 million in 2026, showing that demand for the company's immunotherapy treatment remains strong.
On February 26, 2026, ImmunityBio, Inc. (NASDAQ:IBRX) concluded enrollment in the Phase 2 QUILT 2.005 randomized study, which compared ANKTIVA + Bacillus Calmette-Guérin (BCG) to BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer carcinoma in situ. The trial enrolled 366 patients and randomly assigned them to the two therapy groups ahead of schedule. An interim review conducted by the US Food and Drug Administration found that the combined therapy increased the durability of complete response, with 85% of patients retaining response at six months compared to 57% for BCG alone, and 84% at nine months versus 52%. The firm plans to submit a biologics licensing application in the fourth quarter of 2026.
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy business. It creates next-generation treatments that activate immunogenic pathways to combat cancer and infectious diseases.
While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
How Ethereum Could Stay Secure Even If Today’s Online Locks Stop Working
Cardano Price Prediction: Can ADA Defend $0.22 as Hoskinson Builds a New Programming Language?
VIPAI Asset Sell-Off and Selective Rotation in Crypto
1. Technology stocks fell sharply as investor interest shifted toward energy and selected defensive assets. From October 10 to 16, the Nasdaq 100 declined 5.49% and the S&P 500 fell 1.95%, while the Dow gained 0.67% and WTI crude rose 10.41%. BTC, ETH, and SOL declined 1.27%, 2.65%, and 4.44%, respectively. This week's technology earnings will be an important test of whether revenue growth, margins, and cash flow can justify current valuations. Better-than-expected results could help stabilize markets in the near term. 2. Crypto continues to see pockets of strong activity, but a broad-based altcoin season has yet to materialize. CoinMarketCap's (CMC) Altcoin Season Index stood at 54 as of the October 18 UTC daily observation, below the altcoin-season threshold of 75, while BTC dominance rose to 60.08%. Our proxy leverage ratio fluctuated between 4.00 and 4.07 during the week, showing no sustained increase and suggesting limited appetite for additional leverage. Meanwhile, as major exchanges expand access to traditional financial assets, the recent sell-off in AI-related equities could attract short-term speculative capital away from crypto. Such capital rotation could make it more difficult for a new altcoin season to take hold. 3. Papertrade's loss-to-mine model has generated significant interest across the crypto community. The protocol combines high-leverage derivatives trading with zero slippage and a mechanism that rewards trading losses with PAPER tokens. Across the eight complete UTC days from October 10 to 17, cumulative reported revenue reached approximately $56.08 million, including $51.90 million distributed to token holders. With growing participation from key opinion leaders (KOLs), Papertrade has reportedly ranked among the top three platforms by profitability in the broader market recently. Assets to watch: BTC, ETH, SOL, ARB, OP, SKHYNIX, SKHY, META, TSLA, LRCX, and SPCX. Key research priorities this week: Cash flow performance in technology earnings; the relative discount and holding costs of the two SK Hynix contracts; and U.S. initial jobless claims and PMI data. Weekly market data cover the period through October 16, while research information was verified through October 18. Observation periods are specified separately for each chart.
Why Bernstein Thinks the AI Stock Sell-Off Could Help Small Caps
Crypto prices
More
